The global market for diabetes mellitus and obesity is set
to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound
annual growth rate of 12.7%, according to new Research.
The company’s latest report states that although this growth
is largely attributable to a large increase in the incidence of type 2 diabetes
mellitus (T2DM) and obesity, a number of pipeline T2DM therapeutics are
anticipated to be significant contributors to market growth over the forecast
period, with some even expected to reach blockbuster status.
According to Associate Analyst explains: “Recent approvals
and pipeline products that are expected to be key players during the forecast
period include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535
(semaglutide). The disease cluster is dominated by therapeutics indicated for
type 1 diabetes mellitus (T1DM) and T2DM, and the majority of the pipeline, in
terms of both quantity and quality of products, is attributable to these
indications.
“While products indicated for obesity do not currently have
a large market presence, there are a large number of these products in the
pipeline, with the majority in early stages of development. Of course, the
growth of the disease cluster is driven not only by the rising global incidence
of obesity, but also the subsequent effect that this has on T2DM incidence,
given the intrinsic link between the two diseases.”
Invokana, which is marketed by Johnson & Johnson, is one
of the key players in the disease cluster. It is expected to reach a huge $3.23
billion by 2022, and is set to be approved across T1DM, T2DM and obesity.
Although current top-selling drugs such as Januvia, Novolog and Invokana are
expected to remain dominant within the disease cluster, four of the anticipated
top 10 best-selling drugs of 2022 will be new to market.
According to Associate Analyst concludes: “These products,
which include dapagliflozin propanediol plus saxagliptin, NN-9535 and LixiLan,
are expected to reach blockbuster status and become key players themselves,
indicating the strength and diversity of both the market and the pipeline for
diabetes.”
- Information based on Publisher’s report: Global Diabetes
and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial
Prominence, While High Unmet Need Remains in Weight Loss Treatment
- This report was built using data and information sourced
from proprietary databases, primary and secondary research, and in-house
analysis conducted by Publisher’s team of industry experts.
For
more information Visit at: http://mrr.cm/34N
Related Report;
Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators
and Kinase Inhibitors Dominate First-in-Class Product Innovation - Visit at - http://mrr.cm/34x
No comments:
Post a Comment
Note: only a member of this blog may post a comment.